Who is the CEO of Vivesto AB?

Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D. is a business executive who currently serves as the CEO of Vivesto AB.

What is the Revenue Growth of Vivesto AB?

Revenue growth data for Vivesto AB is currently unavailable.

What is Vivesto AB operating Margin?

Vivesto AB operating margin is -35144.73% which shows how much profit OASMY earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Vivesto AB operate?

Vivesto AB falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Vivesto AB revenue growth?

Revenue growth data for Vivesto AB is currently unavailable.

Vivesto AB

OASMY•PNK

HealthcareDrug Manufacturers - Specialty & Generic

$0.02

$0.00(0.00%)

Vivesto AB (OASMY) Stock Overview

Explore Vivesto AB’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OASMYStats details for OASMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for OASMYAnalyst Recommendations details for OASMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

CEO

Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.

Employees

Headquarters

Gustav III:s Boulevard 46, Solna

Founded

2015